For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Ironwood Pharmaceuticals, Inc.

USPTO Granted Patents = 44

CIPO Patents = 6

EPO Patents = 25

Trademarks = 13

Forward Citations = 322

Loading Chart...

Loading Chart...

67 inventors (with patents filed for the assignee):

Mark G Currie (24 out of 70 patents)

Angelika Fretzen (18 out of 21 patents)

Takashi Nakai (10 out of 23 patents)

4. Joel D Moore (10 out of 27 patents)

5. Nicholas Robert Perl (9 out of 16 patents)

6. Ara Mermerian (9 out of 18 patents)

7. G Todd Milne (9 out of 16 patents)

8. Shalina Mahajan-Miklos (9 out of 11 patents)

9. Rajesh R Iyengar (8 out of 26 patents)

10. Timothy Claude Barden (8 out of 18 patents)

11. Daniel P Zimmer (8 out of 10 patents)

12. Thomas Wai-Ho Lee (7 out of 17 patents)

13. Marco Kessler (7 out of 9 patents)

14. Charles Kim (7 out of 7 patents)

15. Thea Norman (6 out of 39 patents)

Core Competencies:

Linaclotide

Gastrointestinal Disorders

sGC Stimulators

FAAH Inhibitors

Imidazotriazinone Compounds

Bile Acid Sequestrants

CRTH2 Modulators

Asthma Treatments

Polymorphs

Anxiolytic Compounds

Heart Failure Treatments

NONOate Derivatives

44 patents: Sort by Forward Citations

1. 10702576 - Stable formulations of linaclotide (2020-07-07),

2. 10675325 - Stable formulations of linaclotide (2020-06-09),

3. 10618938 - Compositions for colon cleansing and the treatment of gastrointestinal disorders (2020-04-14),

4. 10266529 - Salts, co-crystals, and polymorphs of an anxiolytic compound (2019-04-23),

5. 10189809 - SGC stimulators (2019-01-29),

6. 10183021 - sGC stimulators (2019-01-22),

7. 10047095 - sGC stimulators (2018-08-14),

8. 9969742 - Imidazotriazinone compounds (2018-05-15),

9. 9840536 - Methods and compositions for the treatment of gastrointestinal disorders (2017-12-12),

10. 9745296 - Salts, co-crystals, and polymorphs of an anxiolytic compound (2017-08-29),

11. 9725453 - Imidazotriazinone compounds (2017-08-08),

12. 9708371 - Treatments for gastrointestinal disorders (2017-07-18),

13. 9657012 - FAAH inhibitors (2017-05-23),

14. 9650417 - Treatments for gastrointestinal disorders (2017-05-16),

15. 9617305 - Treatments for gastrointestinal disorders (2017-04-11),

Ironwood Pharmaceuticals, Inc. is a leading biotechnology company focused on the development and commercialization of innovative therapies for gastrointestinal (GI) diseases. Their mission is to advance the treatment of GI diseases, including irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC), and others. With a commitment to patients and scientific rigor, Ironwood strives to improve the lives of millions affected by these conditions. For more information, please visit their website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

44 Patents

#51 in Cambridge, MA

#441 in Massachusetts

#7,675 in US

#15,297 in the World

Cambridge, MA, United States of America

Ironwood Pharmaceuticals, Inc.

Forward Citations = 322

67 inventors:

Mark G Currie (24 out of 70 patents)

Angelika Fretzen (18 out of 21 patents)

Takashi Nakai (10 out of 23 patents)

4. Joel D Moore (10 out of 27 patents)

5. Nicholas Robert Perl (9 out of 16 patents)

Please report any incorrect information to support@idiyas.com

Loading…